By Mill Chart
Last update: Nov 6, 2023
Take a closer look at EXELIXIS INC (NASDAQ:EXEL), an affordable growth stock uncovered by our stock screener. NASDAQ:EXEL boasts strong growth prospects and excels in financial health indicators, all while maintaining a reasonable valuation. Let's break it down further.
ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:EXEL was assigned a score of 7 for growth:
To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NASDAQ:EXEL has achieved a 6 out of 10:
ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NASDAQ:EXEL, the assigned 7 for health provides valuable insights:
ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NASDAQ:EXEL, the assigned 7 is a significant indicator of profitability:
More Affordable Growth stocks can be found in our Affordable Growth screener.
Check the latest full fundamental report of EXEL for a complete fundamental analysis.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
42.88
-0.16 (-0.37%)
Find more stocks in the Stock Screener
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings growth, expanding margins, and solid cash flow, making it a standout for growth investors following Louis Navellier’s strategy.
EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.
EXELIXIS INC (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a candidate for value investors.
EXELIXIS INC (NASDAQ:EXEL) meets Minervini’s Trend Template with strong technicals and high growth momentum, making it a standout in biotech. Review its full technical and fundamental strengths before considering an investment.